Breast Cancer Stage IV
Conditions
Keywords
non-visceral metastasis, Huaier granule, randomized controlled, prospective clinical study
Brief summary
This is a multicenter, open-label, randomized controlled, prospective clinical study to evaluate the efficacy and safety of Huaier Granules in patients with advanced breast cancer without visceral metastasis.
Detailed description
This study used a blank control design and included at least 384 subjects. The experimental group and control group were randomized in a 2:1 ratio (at least 256 subjects in the experimental group and at least 128 subjects in the control group). Patients in the experimental group were treated with Huaier Granules (10g/dose, 3 times/day), while undergoing routine diagnosis and treatment; The control group received routine diagnosis and treatment, but did not take Huaier granules until the subjects experienced disease progression or intolerance.
Interventions
DRUGHuaier Granule
10g each time, three times a day
Sponsors
LinkDoc Technology (Beijing) Co. Ltd.
Huazhong University of Science and Technology
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18 years old ≤ age ≤ 75, regardless of gender. * For breast cancer patients who are clinically or pathologically diagnosed as non visceral metastasis, if the patient has only local recurrence or metastasis, the clinician judges that it is not suitable or refuses to use local treatment with radical intensity, such as surgical resection or radiotherapy. * Prior to enrollment, no more than first-line chemotherapy/endocrine therapy/targeted therapy/immunotherapy were allowed;If the patient has previously received first-line therapy, the outcome of treatment should be clinically assessed as disease progression or intolerance. * There is at least one measurable lesion that meets the RECIST 1.1 standard, or only bone metastases (including osteolytic lesions or mixed lesions). * The liver and kidney functions meet the following conditions: AST and ALT\<3 ULN, total bilirubin ≤ 2 ULN, and blood creatinine\<1.5 ULN. * Other laboratory tests meet the following requirements: Hb ≥ 9g/dl, platelet count ≥ 60 × 10\^9/L, absolute neutrophil count\>1.0 × 10\^9/L. * Expected survival time ≥ 12 weeks. * The patient's ECOG physical state score is 0 or 1. * The subjects participated in the study voluntarily and signed an informed consent form.
Exclusion criteria
* Any other malignancies diagnosed within 5 years prior to enrollment, except those with a low risk of metastasis and death (5-year survival \> 90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ. * There is visceral metastasis of breast cancer. * Patients with advanced (local recurrence or metastasis) breast cancer who plan to receive radical local treatment. * Serious infections (CTCAE\>Level 2) have occurred within 4 weeks prior to enrollment, such as severe pneumonia, bacteremia, infection complications that require hospitalization; Symptoms and signs of infection or the need for oral or intravenous antibiotic treatment within 2 weeks prior to enrollment, except for prophylactic use of antibiotics. * Suffering from severe acute and chronic diseases. * Suffering from severe diabetes whose blood sugar cannot be effectively controlled. * Patients who cannot take oral medication or are allergic to the ingredients of Huaier granules. * Drug abusers, or those who suffer from psychological or mental illnesses that may interfere with research compliance. * Pregnant or lactating women. * The researcher believes that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Investigator evaluated progression free survival | start of treatment until 3.5-year follow-up | The time from randomization to the first occurrence of disease progression or death from any cause. As long as the subject experiences either disease progression or death first, it reaches the endpoint of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival(OS) | start of treatment until 3.5-year follow-up | The time from randomization to death (from any cause) |
| Clinical benefit rate (CBR) | start of treatment until 3.5-year follow-up | The percentage of patients with advanced breast cancer who achieved a complete response, partial response, or stable disease for at least six months after treatment |
| Objective response rate (ORR) | start of treatment until 3.5-year follow-up | Proportion of patients whose breast cancer has shrunk to a predetermined volume and maintains a minimum time limit |
| Adverse reactions | start of treatment until 3.5-year follow-up | Harmful reactions of Huaier granules that are unrelated to the purpose of the medication under normal usage and dosage |
Other
| Measure | Time frame | Description |
|---|---|---|
| Reduction rate of immune-related cytokines | The baseline period，12th week±14 days and 168th week±14 days | During the treatment process, the decrease rate of immune related cytokines（Such as IL-1 β， IL-2，IL-4，IL-5，IL-6，IL-8，IL-10，IL-12，IL-17，TNF- α， IFN- α， IFN- γ etc.） compared to the baseline period |
Countries
China
Contacts
Primary ContactZhimin Shao, PhD
Backup ContactLiang Huang, PhD
Outcome results
None listed